The persistent capability of CRPC to become resistant to various means of suppression of AR signalling suggests that a multipronged approach to cancer treatment is required and leads to the research question: what drives prostate cancer aggressiveness and CRPC progression? The gene discussed is AR; the disease is prostate carcinoma.